| Biomarkers in the management of heart failure. | |
| | |
MedLine Citation:
|
PMID: 21063930 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
OPINION STATEMENT: Biomarkers, especially natriuretic peptides such as B-type natriuretic peptide (BNP) and N-terminal-proBNP (NT-proBNP), are a valuable addition to standard clinical assessment in the diagnosis and prognosis of heart failure (HF). Furthermore, there is an increasing amount of evidence suggesting that natriuretic peptide-guided HF management may improve mortality, morbidity, and cost effectiveness. This work focuses on the use of BNP or NT-proBNP for the outpatient management of patients with chronic HF. |
| | |
Authors:
|
Han-Na Kim; James L Januzzi |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current treatment options in cardiovascular medicine Volume: 12 ISSN: 1534-3189 ISO Abbreviation: Curr Treat Options Cardiovasc Med Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-10 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9815942 Medline TA: Curr Treat Options Cardiovasc Med Country: United States |
Other Details:
|
Languages: eng Pagination: 519-31 Citation Subset: - |
Affiliation:
|
Cardiology Division, Massachusetts General Hospital, 32 Fruit Street, Yawkey 5984, Boston, MA, 02114, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Neuromodulation and the role of electrodiagnostic techniques.
Next Document: Management of anemia and iron deficiency in heart failure.